News from bionity.com
Venomous crustacean from Mayan underwater caves provides new drug candidates
Zootoxins affect a wide range of physiological processes and are therefore of great interest for drug research. An international study led by Björn von Reumont of Goethe University Frankfurt has identified novel toxins from the cave-dwelling underwater crustacean Xibalbanus tulumensis that inhibit v...
Towards a better understanding of the human immune defense against RNA viruses
An international research team led by Prof. Dr. Janosch Hennig from the University of Bayreuth has discovered how the TRIM25 protein contributes to defense against RNA viruses whose genetic material is contained as ribonucleic acid (RNA). The results provide a better understanding of the molecular m...
Innovative approach to treat autism spectrum disorders
In 2022, Dr. Özgür Genç together with Professor Peter Scheiffele from the Biozentrum, University of Basel, founded the startup Translation-X with the goal of developing novel therapeutics for autism spectrum disorders. They have now received 150’000 Swiss Francs investment from the Venture Kick init...
It all adds up: Study finds forever chemicals are more toxic as mixtures
A first-of-its-kind study has measured the toxicity of several types of per- and polyfluoroalkyl substances (PFAS), better known as “forever chemicals,” when mixed together in the environment and in the human body. The good news: Most of the tested chemicals’ individual cytotoxicity and neurotoxicit...
Nobel Prize in Physiology or Medicine for the discovery of microRNA
The Nobel Assembly at Karolinska Institutet has decided to award the 2024 Nobel Prize in Physiology or Medicine jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. This year’s Nobel Prize honors two scientists for their discove...
Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery
Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker’s biophysical portfolio for the analysis of molecular interactions and kinetics, ...
Gene therapy against hemophilia
Cell and gene therapies are on the rise. This is a new glimmer of hope for people with previously untreatable or barely treatable diseases. Another new therapeutic method has now been added to the list: gene therapy for hemophilia, also known as bleeding disorder. The Hemophilia Center at Hannover M...
Pulmonary carcinoids:Mortal or immortal cancer cells?
Pulmonary carcinoids are rare tumors of the lung with extremely varied clinical courses. In many patients, they behave like benign tumors; surgical removal of the tumor leads to a complete cure in these patients. In some patients, however, the tumor grows aggressively and metastasizes, with poor cha...
Stardust in the bathroom
Widespread skin diseases such as psoriasis or neurodermatitis are difficult to treat. Together with an industrial partner, Empa researchers have found an innovative solution: Nanoceramic "stars" create tiny skin lesions and allow therapeutic molecules to reach their site of action. When material sci...
Beckman Coulter Life Sciences Names Joe Fox President
Beckman Coulter Life Sciences announces the appointment of Joe Fox as President of the company effective immediately. Fox joins Beckman Coulter Life Sciences from SCIEX, also an Operating Company of Danaher Corporation, where he held positions of increasing responsibility over the past 13 years, mos...